Target
taxane
6 abstracts
Abstract
A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial.Org: Yonsei University College of Medicine, Asan Medical Center, University of Ulsan College of Medicine, Gangnam Severance Hospital, Seoul St. Mary's Hospital,
Abstract
Genomic alterations in DNA damage response (DDR) genes in HR+/HER2- metastatic breast cancer (mBC) and impact on clinical efficacy with sacituzumab govitecan (SG): Biomarker results from TROPICS-02 study.Org: David Geffen School of Medicine at UCLA, University of California Irvine, Jonsson Comprehensive Cancer Center, Los Angeles, CA, Gilead Sciences, Inc.,
Abstract
FGFR3-mutated urothelial carcinoma of bladder and upper tract including ureter and renal pelvis: A comparative genomic profiling study.Org: Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Department of Medicine, Division of Hematology/Oncology, University of Washington, Fred Hutchinson Cancer Center, Department of Pathology, SUNY Upstate Medical University,
Abstract
Treatment (Tx) patterns, efficacy and safety of eribulin for advanced and heavily pretreated breast cancer (ABC): Updated results from a single-center, real-world study.Org: Jiaotong University,
Abstract
Enrichment of somatic mosaic states involving DNA damage response and repair genes in patients treated with 177Lutetium.Org: Mayo Clinic Arizona, Phoenix, AZ, Mayo Clinic Florida, Jacksonville, FL, Mayo Clinic, Rochester, MN, Division of Medical Oncology, Mayo Clinic, Rochester, MN, Department of Hematology-Oncology, Mayo Clinic Florida, Jacksonville, FL, Mayo Clinic Comprehensive Cancer Center, Phoenix, AZ,
Abstract
Phase 3 randomized study for evaluation of physician choice Rx and triple metronomic as second-line therapy in head and neck cancer (CRSF 2021-HN-001).Org: Narayana Multispeciality Hospital, Tata Memorial Hospital, Homi Bhabha cancer hospital and research centre, Regency Hospital, National Cancer Insitute,